

AMENDMENTS

In the Specification:

On page 5, between lines 3 and 4, please insert the following new paragraph:

E1 --Such methods include those wherein said subject is afflicted with metastatic prostate cancer; and/or wherein said subject has been surgically treated to excise said tumor but is at risk for recurrence and wherein said subject is optionally in a "neoadjuvant" setting prior to surgical excision of said prostate tumor; or wherein said subject is a potential prostate tumor-bearing subject at risk for said tumor.--

In the Claims:

13. (Amended) A method to elicit an antitumor immune response to prostate tumors in a subject, which method comprises

administering to said subject at least one active ingredient formulated for administration to said subject,

wherein said active ingredient comprises or expresses at least one antigen over-represented in the prostate gland or an immunologically effective portion thereof,

E2 wherein said antigen is an immunologically reactive portion of human prostate-specific antigen (PSA); or

human prostate-specific membrane antigen (PSMA) or an immunologically effective portion thereof; or

human prostate-specific membrane antigen (PSMA) or an immunologically effective portion thereof; or

prostatic acid phosphatase (PAP) or an immunologically reactive portion thereof; or mixtures of the foregoing; or

wherein said active ingredient comprises a nucleic acid that generates said antigen or antigens *in*

situ.